Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.
Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.
复制标题
磺胺甲恶唑和甲氧苄啶化学预防艾滋病卡氏肺孢子虫肺炎的安全性和有效性。
DOI：
10.1001/jama.1988.03720080019021
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
L. La Voie
中科院分区：
文献类型：
--
作者：
M. Fischl;G. Dickinson;L. La Voie
评价了磺胺甲恶唑和甲氧苄啶预防获得性免疫缺陷综合征（艾滋病）相关卡氏肺孢子虫肺炎的安全性和有效性。60例新诊断为卡波西肉瘤且无机会性感染史的患者被随机分配接受800 mg磺胺甲恶唑和160 mg甲氧苄啶，每日两次或不接受治疗。30例接受磺胺甲恶唑和甲氧苄啶治疗的患者中无一例发生卡氏肺孢子虫肺炎。30例未接受抑制治疗的患者中有16例发生卡氏肺孢子虫肺炎。卡氏肺孢子虫肺炎的发生与卡波西肉瘤的分期、B亚型疾病以及研究入组时CD 4细胞≤ 0.20 × 10（9）/L（200/mm 3）相关。与对照组相比，治疗组的存活患者比例和平均存活时间显著更长。不良反应发生率为50%。
The safety and efficacy of sulfamethoxazole and trimethoprim in the prevention of Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome (AIDS) were evaluated. Sixty patients with a new diagnosis of Kaposi's sarcoma and no history of opportunistic infections were randomly assigned to receive 800 mg of sulfamethoxazole and 160 mg of trimethoprim twice per day or no therapy. None of the 30 patients receiving sulfamethoxazole and trimethoprim developed P carinii pneumonia. Sixteen of the 30 patients receiving no suppressive therapy developed P carinii pneumonia. Development of P carinii pneumonia was associated with the stage of Kaposi's sarcoma, B subtype disease, and the presence of 0.20 X 10(9)/L (200/mm3) or fewer CD4 cells at study entry. The proportion of patients surviving and the mean length of survival were significantly greater in the treatment group compared with the control group. Adverse reactions occurred in 15 patients (50%).